Green Chemistry
Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Search
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.